Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
By Vladimir Torchilin. Nature reviews. Drug discovery, 2014
1,433 citations recorded by the source corpus.
The use of nanoparticulate pharmaceutical drug delivery systems (NDDSs) to enhance the in vivo effectiveness of drugs is now well established. The development of multifunctional and stimulus-sensitive NDDSs is an active area of current research. Such NDDSs can have long circulation times, target the site of the disease and enhance the intracellular delivery of a drug. This type of NDDS can also respond to local stimuli that are characteristic of the pathological site by, for example, releasing an entrapped drug or shedding a protective coating, thus facilitating the interaction between drug-loaded nanocarriers and target cells or tissues. In addition, imaging contrast moieties can be attached to these carriers to track their real-time biodistribution and accumulation in target cells or tissues. Here, I highlight recent developments with multifunctional and stimuli-sensitive NDDSs and their therapeutic potential for diseases including cancer, cardiovascular diseases and infectious diseases.
Subfields: Biomaterials, Biomedical Engineering, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/0535b1b5879f15344d2dba832563a01bd25662c9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomaterials
In Biomedical Engineering
In Molecular Biology
Citations in the corpus
- Nanoparticles in the clinic (2016, background): “, noncolloidal) do not offer.(2,27) Given these advantages, it has been a long-held idea that nanoparticles have the potential to dramatically change clinical care by introducing new, or improving upon current, therapies.”
- Nanogels: an overview of properties, biomedical applications and obstacles to clinical translation (2015, background): “Nanogels not only protect the cargo from degradation and elimination but also participate actively in the delivery process due to their characteristic properties like stimuli-responsive behavior, softness and swelling to help achieve a controlled, triggered response at the target site [3-9].”
- The Smart Drug Delivery System and Its Clinical Potential (2016, background): “On one hand, concentrations of GSH in blood and normal extracellular matrices are reported to be 2-20 μM, at the same time GSH levels within cancer cell ranges from 2 to 10 mM, which is 100- to 5000- fold higher than the normal ranges [34].”